IP Library Granted Patent US 9,732,082
Granted Patent B2
US 9,732,082 · App. 14/564,568 · Granted Aug 15, 2017

Purinone derivative

Inventors: Shingo Yamamoto (Osaka, JP); Toshio Yoshizawa (Osaka, JP)
Assignee: ONO PHARMACEUTICAL CO., LTD.
C07D473/34A61K31/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,082
App. No.
14/564,568
Granted
Aug 15, 2017
Kind
B2
Abstract

Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

Claims (23)

1. A method of treating a Btk-related disease selected from B-cell non-Hodgkin's lymphoma, lupus, systemic lupus erythematosus, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, and juvenile arthritis, comprising administering to a mammal in need thereof an effective amount of a compound represented by general formula (I):

(in the formula,

L represents (1) —O—, (2) —S—, (3) —SO—, (4) —SO 2 — (5) —NH—, (6) —C(O)—, (7) —CH 2 —O—, (8) —O—CH 2 —, (9) —CH 2 —, or (10) —CH(OH)—;

R 1 represents (1) a halogen atom, (2) a C 1-4 alkyl group, (3) a C 1-4 alkoxy group, (4) a C 1-4 haloalkyl group, or (5) a C 1-4 haloalkoxy group;

ring1 represents a benzene, cyclohexane, or pyridine ring, which may be substituted by from one to five substituents each independently selected from the group consisting of (1) halogen atoms, (2) C 1-4 alkyl groups, (3) C 1-4 alkoxy groups, (4) nitrile, (5) C 1-4 haloalkyl groups, and (6) C 1-4 haloalkoxy groups, wherein when two or more substituents are present on ring1, these substituents may form a 4- to 7-membered cyclic group together with the atoms in ring1 to which these substituents are bound;

ring2 represents a 4- to 6-membered nitrogenous saturated heterocycle, which is substituted by from one to three —K—R 2 ;

K represents —C(O)—, (wherein the bond on the left is bound to the ring2);

R 2 represents (1) a C 1-4 alkyl, (2) a C 2-4 alkenyl, or (3) a C 2-4 alkynyl group, each of which may be substituted by from one to five substituents each independently selected from the group consisting of (1) NR 3 R 4 , (2) halogen atoms, (3) CONR 5 R 6 , (4) CO 2 R 7 , and (5) OR 8 ;

R 3 and R 4 each independently represent (1) a hydrogen atom, or (2) a C 1-4 alkyl group which may be substituted by OR 9 or CONR 10 R 11 ;

R 3 and R 4 may, together with the nitrogen atom to which they are bound, form a 4- to 7-membered nitrogenous saturated heterocycle, which may be substituted by an oxo group or a hydroxyl group;

R 5 and R 6 each independently represent (1) a hydrogen atom, (2) a C 1-4 alkyl group, or (3) a phenyl group;

R 7 represents (1) a hydrogen atom or (2) a C 1-4 alkyl group;

R 8 represents (1) a hydrogen atom, (2) a C 1-4 alkyl group, (3) a phenyl group, or (4) a benzotriazolyl group;

R 9 represents (1) a hydrogen atom or (2) a C 1-4 alkyl group;

R 10 and R 11 each independently represent (1) a hydrogen atom or (2) a C 1-4 alkyl group;

n represents an integer from 0 to 4;

m represents an integer from 0 to 2; and

when n is two or more, the R 1 's may be the same as each other or may differ from one another), an optical isomer thereof or their mixture, a salt thereof, a solvate thereof, or an N-oxide thereof.

2. The method according to claim 1 , wherein R 2 is a C 2-4 alkenyl group or a C 2-4 alkynyl group, each of which may be substituted by from one to five substituents each independently selected from the group consisting of (1) NR 3 R 4 , (2) halogen atoms, (3) CONR 5 R 6 , (4) CO 2 R 7 , and (5) OR 8 .

3. The method according to claim 1 , wherein the 4- to 6-membered nitrogenous saturated heterocycle is an azetidine, pyrrolidine, or piperidine ring.

4. The method according to claim 1 , wherein the compound represented by general formula (I) is the compound represented by general formula (I-1)

(in the formula, ring1-1 represents a benzene, cyclohexane, or pyridine ring, each of which may be substituted by from one to five substituents each independently selected from the group consisting of (1) halogen atoms, (2) C 1-4 alkyl groups, (3) C 1-4 alkoxy groups, (4) nitrile, and (5) CF 3 , and ring2-1 represents a 4- to 6-membered nitrogenous saturated heterocycle, which is substituted by from one to three —K—R 2 , wherein the other symbols have the same definitions as above).

5. The method according to claim 4 , wherein R 2 is a C 2-4 alkenyl group or a C 2-4 alkynyl group, each of which may be substituted by from one to five substituents each independently selected from the group consisting of (1) NR 3 R 4 , (2) halogen atoms, (3) CONR 5 R 6 , (4) CO 2 R 7 , and (5) OR 8 .

Priority Claims (1)
JP 2010-123727 · May 31, 2010 · national
Continuity (2)
Continuation 13700774
Related Publication 20150094299A1 · Apr 2, 2015